Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing innovative therapeutics for anxiety, depression, and addiction, announces CEO Dr. Joseph Tucker's participation in the Wonderland conference in Miami, FL, from November 3-5, 2022. Dr. Tucker will speak on the panel entitled Synthetic vs Natural Debate on November 5 at 12:00 p.m. ET. Interested parties can schedule one-on-one meetings with Enveric's management by contacting KCSA Strategic Communications.

Enveric Biosciences (NASDAQ: ENVB) has announced the nomination of EB-373 as the lead candidate from its EVM201 program, targeting anxiety disorders. This milestone coincides with preclinical data presented at the International Neurology & Brain Disorders Conference. EB-373 is set to advance through key preclinical studies aimed at filing an IND application with the FDA in late 2023. The company also disclosed the discontinuation of the first-generation EVM101 program due to promising results from its newer drug candidates.

Enveric Biosciences (NASDAQ: ENVB) announced the presentation of its lead programs' results at the 6th International Neurology & Brain Disorders Conference in Orlando, Florida, from October 24-26, 2022. The poster presentations will showcase innovative drug candidates for anxiety, depression, and addiction disorders, highlighting EVM201's novel psilocin prodrugs and EVM301's methods for future drug candidate discovery. Dr. Peter Facchini expressed optimism about advancing their drug discovery program aimed at enhancing mental health treatments.

Enveric Biosciences (NASDAQ: ENVB) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York City on September 12-14, 2022. President & COO Avani Kanubaddi will present on September 14 at 2:00 p.m. ET. Attendees can register here. Enveric focuses on developing innovative psychedelic-inspired medicines for mental health.

Enveric Biosciences (NASDAQ: ENVB) has appointed three experienced leaders to its Board of Directors: Michael D. Webb, Bevin O’Neil, and Frank Pasqualone. These new board members bring decades of expertise in healthcare, business operations, and global market dynamics. Dr. Joseph Tucker, CEO, expressed enthusiasm for their contributions at this pivotal time for the company, which is focused on developing psychedelic-inspired mental health medicines.

Enveric Biosciences, Inc. (NASDAQ: ENVB) has completed a registered direct offering of 375,000 shares of common stock, raising approximately $8 million before expenses. Additionally, a private placement was conducted for 625,000 shares under similar terms. The offerings included preferred investment options that allow the purchase of an equal number of shares at an exercise price of $7.78. Proceeds will support working capital and corporate purposes. The company has also amended existing warrants to reduce their exercise price to $7.78 from $27.50.

Enveric Biosciences (NASDAQ: ENVB) has entered into definitive agreements for the purchase of 1,000,000 shares of its common stock through a registered direct offering and private placement, priced at $8.00 per share. The total expected gross proceeds from these offerings are approximately $8 million, intended for working capital and corporate purposes. Additionally, existing warrants will be amended to reduce their exercise price to $7.78 per share. The closing is anticipated around July 26, 2022, subject to customary conditions.

Enveric Biosciences (NASDAQ: ENVB) announced a 1-for-50 reverse stock split effective July 14, 2022. This adjustment will reduce the outstanding shares from approximately 52.7 million to 1.05 million. Shareholders will not need to exchange certificates, as adjustments will be made automatically for shares held in brokerage accounts. This split is aimed at improving the company's stock price and maintaining its listing on the Nasdaq Capital Market. The company focuses on developing psychedelic-inspired mental health medicines.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on psychedelic-inspired mental health treatments, announced participation in three key conferences: the A.G.P. Summer Healthcare Conference on June 21-22, the Gravitas Los Angeles Summit on June 22, and the H.C. Wainwright Mental Health Conference on June 27. CEO Dr. Joseph Tucker will represent the company at these events, highlighting its commitment to developing innovative solutions for mental health issues affecting patients globally.